AstraZeneca, Ironwood agree US licensing deal for gout treatment
Updated : 10:06
AstraZeneca said it had entered a licensing agreement with Ironwood Pharmaceuticals over exclusive US rights to Zurampic, which is used to treat hyperuricemia associated with uncontrolled gout.
Ironwood will get rights to Zurampic and exclusive US rights to the fixed-dose combination of lesinurad and allopurinol.
AstraZeneca said it planned to submit the fixed-dose combination programme for regulatory review in the second half of 2016.
Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265m and tiered single-digit royalties on product sales.
AstraZeneca will make and supply Zurampic, provide certain support and services to Ironwood and undertake the FDA post-approval commitment on its behalf.
The agreement does not impact AstraZeneca's financial guidance for 2016.